Revenue increased to ¥62.39 billion from ¥51.68 billion in the previous year. Operating profit climbed to ¥6.36 billion from ¥4.99 billion, and pretax profit reached ¥6.18 billion, up from ¥4.46 billion.
Earnings per share were ¥111.18, compared with ¥122.94 for the year ended Sept. 30, 2025. Fuji Pharma Co. Ltd. trades under ticker 4554.TO.

Comments (0)
No comments yet. Be the first!